Company intelligence / Profile preview

Phraxis

Minneapolis, Minnesota, United Statesphraxis.com ↗

Ownership: Private
Employees: ~4
Development stage: Commercial

Overview

Phraxis has developed and received FDA approval for the EndoForce™ Connector, a patented endovascular implant that enables minimally invasive creation of arteriovenous grafts (AVGs) for hemodialysis. In its pivotal clinical trial, EndoForce™ demonstrated a 92% cumulative patency rate at six months—surpassing traditional suture techniques—and showed strong procedural success and technical reliability. The product is now commercially available in the U.S.

Therapeutic areas: Nephrology
Modalities: DeviceImplantable medical device (Endovascular implant)
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Phraxis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phraxis.

Explore the full profile